Announced Date: 2024-05-26 (May 26, 2024)
Licensor: MediLink Therapeutics (China)
Licensee: BioNTech
.
Scope of Authority:
BioNTech will receive an exclusive option to an exclusive global license to apply MediLink’s TMALIN® antibody-drug conjugate (ADC) platform, for several novel targets chosen by BioNTech.
.
MediLink will hold the right of first negotiation for future collaboration of these ADC product candidates if BioNTech wishes to exclusively license or assign rights in such ADC product candidates solely on the Mainland China market or Mainland China market together with one or more of the markets including of Hong Kong, Macau or Taiwan region.
.
Payment Detail:
MediLink will receive
Upfront payment of $25 million,
Development, regulatory and sales milestone payments potentially totaling up to $1.8 billion.
Tiered royalties on potential future global annual net sales.
.
Link:
. MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech
.
Note:
Chinese Name of “MediLink Therapeutics“，宜联生物
